Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

June 1st 2018

This Week in Managed Care: June 1, 2018

This week, the top managed care stories include Senator Bill Cassidy's new plan to lower healthcare costs; policy recommendations from the American Diabetes Association on how to lower insulin prices; and coverage from the American Society of Clinical Oncology annual meeting.

June 1st 2018

New Immunotherapy Increases Survival Time for Patients With Brain Cancer

Samantha DiGrande

A new immunotherapy referred to as the "Toca regimen" is being investigated in a phase 2/3 randomized, multicenter, open-label trial.

May 31st 2018

Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma

Laura Joszt, MA

Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.

May 31st 2018

Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers

Surabhi Dangi-Garimella, PhD

A retrospective analysis conducted by researchers at the University of Louisville has found that less than 2% of the more than 7.5 million eligible smokers were screened for lung cancer in 2016 despite recommendations by the United States Preventive Services Task Force (USPSTF). These results will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, Chicago, Illinois.

May 31st 2018

After Two Decades of Decline, Prostate Cancer Mortality Rates Have Stabilized

Jaime Rosenberg

Mortality rates have stabilized and incidence rates of late-stage disease have started to increase after 2 decades of decreasing rates. At the same time, rates of prostate-specific antigen screening have declined.

May 30th 2018

Start Screening for Colon Cancer at Age 45, Not 50, ACS Recommends

Allison Inserro

Rates of colon cancer are increasing in younger people, and as a result the American Cancer Society (ACS) is recommending that screening should start 5 years earlier, at 45 years of age rather than 50.

May 30th 2018

Remote Monitoring Can Reduce Radiation-Related Symptoms in Head and Neck Cancer

Surabhi Dangi-Garimella, PhD

Use of the mobile and sensor technology, CYCORE—CYberinfrastructure for COmparative Effectiveness Research—to remotely monitor symptoms in patients with head and neck cancer (HNC) undergoing radiation therapy found CYCORE patients had lower symptoms overall and specific to HNC. These results are a part of the research to be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, Chicago, Illinois.

May 30th 2018

Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC

Jaime Rosenberg

Pembrolizumab significantly improved overall survival (OS) and progression-free survival (PFS) as first-line treatment for squamous non–small cell lung cancer (NSCLC) in the pivotal phase 3 KEYNOTE-407 trial.

May 29th 2018

Clotting Factor Associated With Greater Metastases in Certain Lung Cancers

Samantha DiGrande

Immune cells that promote clotting within tumors in a specific type of lung cancer are actually assisting the tumor to spread throughout the body, according to a recent study published in Nature Communications.

May 29th 2018

Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer

Surabhi Dangi-Garimella, PhD

During a press cast hosted by the American Society of Clinical Oncology ahead of the annual meeting, women with HER2-positive early-stage breast cancer who were treated with trastuzumab (Herceptin) for 6 months had a similar rate of disease-free survival as women who received the drug for 12 months, which is the current standard of care.

May 29th 2018

Dr Charles Saunders: Practices Don't Integrate Technology Well

In general, practices and health systems don’t do a good job of integrating technology into practice, partly because most of the technology they use isn’t well suited to their needs, explained Charles Saunders, MD, CEO of Integra Connect.

May 27th 2018

Dr Donna Hansel Discusses Research on Human Bladder Cancer Cells

Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research.

May 26th 2018

Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments

Laura Joszt, MA

A new study analyzed the burden of multiple myeloma around the world, as well as access to effective treatments. From 1990 to 2016, incident cases and deaths from the disease have grown substantially.

May 25th 2018

5 Abstracts to Look for at ASCO 2018

Samantha DiGrande

Here is a preview of 5 of the biggest trial results to be presented at the American Society of Clinical Oncology (ASCO)'s Annual Meeting to be held on June 1 to 5, 2018, in Chicago, Illinois.

May 25th 2018

Dr James Hamrick Highlights How Technology Eases Burdens on Research Staff

Technology can be used to make it easier for patients and practices to participate in clinical trials, while also easing some of the burden on research staff, said James Hamrick, MD, MPH, Kaiser Permanente and Flatiron Health.

May 23rd 2018

Ian Manners Outlines Pharma's Participation in Providing Financial Assistance for Patients

Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.

May 23rd 2018

Cancer Mortality in the United States Continues to Decline

Jaime Rosenberg

While cancer incidence rates have decreased among men, they've remained stable among women and have increased among children; however, there has been an overall decline in mortality rates among men, women, and children.

May 22nd 2018

All-Cause Healthcare Payments Substantial for Younger Adults With Depression, and Other Poster Findings at ISPOR

Laura Joszt, MA

Posters presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, highlighted healthcare costs for patients with treatment-resistant depression, off-label drug use in children with depressive disorder, and incidence of depression in patients diagnosed with late-stage cancer.

May 22nd 2018

Rucaparib May Have Potential Clinical Benefit for Advanced Pancreatic Cancer

Jaime Rosenberg

Rucaparib, the PARP inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

May 21st 2018

Dr Mark Fleury on 21st Century Cures and Cancer Care

The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).

May 20th 2018

Michele McCourt Explains CancerCare's Role in Supporting Patients

Beyond helping with co-payment assistance for patients with cancer, CancerCare helps with practical and emotional supports for patients, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

May 19th 2018

Podcast: This Week in Managed Care—A Plan to Drive Down Drug Prices and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

May 18th 2018

This Week in Managed Care: May 18, 2018

This week, the top managed care stories included President Donald Trump's plan to drive down drug prices; the FDA approved the first biosimilar of the year; a study found rapid uptake of PD-1 agents after FDA approval.

May 17th 2018

Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women

Jaime Rosenberg

While immune checkpoint inhibitors significantly improve overall survival in both sexes, the magnitude of benefit is dependent on sex, according to new study findings.

May 16th 2018

Dr Mark Soberman Discusses Integrated Care Teams in Oncology

Integrated care teams will create more value for the patient, but there are multiple challenges in the creation of these teams, said Mark Soberman, MD, MBA, FACS, former president of the Association of Community Cancer Centers.

May 15th 2018

Thomas Asfeldt Highlights 3 Key Challenges to Creating Integrated Cancer Care Teams

Creating integrated cancer care teams is part of a paradigm shift that requires thinking of care delivery in a different way, explained Thomas Asfeldt, MBA, RN, director of Outpatient Cancer Services at Sanford Cancer Center.

May 14th 2018

Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval

Jaime Rosenberg

In the 4 months following their approvals, pembrolizumab and nivolumab reached more than 60% of eligible patients with melanoma, non-small cell lung cancer, and renal cell carcinoma.

May 14th 2018

Dr Oliver Dorigo Discusses an Interdisciplinary Approach to Care in Gynecologic Oncology

An interdisciplinary approach to patient care is very important because the treatment of gynecologic cancers can be very complex, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.

May 12th 2018

Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care

We have to decide if we’re prepared to not cover low-value treatments as we shift to value-based care, said Robert Navarro, PharmD, clinical professor, College of Pharmacy, University of Florida.

May 11th 2018

USPSTF Recommends Patient Choice for Prostate Cancer Screening

Jaime Rosenberg

The US Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make their own decision on whether or not to be screened periodically for prostate cancer after they have had a conversation with their physician on potential benefits and harms.

...

46 47 48 49 50 51 52 53 54

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions